What is Regulus Therapeutics Operating Cash Flow per Share?
Regulus Therapeutics's operating cash flow per share for the
three
months ended in Sep. 2024 was $-0.14.
Regulus Therapeutics's operating cash flow per share for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.93.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 26.70% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 49.40% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 40.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Regulus Therapeutics's Operating Cash Flow per Share or its related term are showing as below:
RGLS'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -13.6 Med: 37.05 Max: 75.7
Current: 26.7
During the past 13 years, Regulus Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 75.70% per year. The lowest was -13.60% per year. And the median was 37.05% per year.
RGLS's 3-Year OCF Growth Rate is ranked better than 76.11% of 1193
companies
in the Biotechnology industry
Industry Median: 3.6
vs RGLS: 26.70
Regulus Therapeutics Operating Cash Flow per Share Historical Data
The historical data trend for Regulus Therapeutics's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Regulus Therapeutics Operating Cash Flow per Share Chart
Competitive Comparison of Regulus Therapeutics's Operating Cash Flow per Share
For the Biotechnology subindustry, Regulus Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regulus Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regulus Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Regulus Therapeutics's Price-to-Operating-Cash-Flow falls into.
Regulus Therapeutics Operating Cash Flow per Share Calculation
Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.
Regulus Therapeutics's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.93
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regulus Therapeutics Operating Cash Flow per Share Related Terms
Thank you for viewing the detailed overview of Regulus Therapeutics's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RGLS has been successfully added to your 